Leveraging Innovation for Precision Medicine



Strong scientific and clinical rationale for novel small molecule PRMT5 inhibitor


  • PRMT5 is the predominant Type II PRMT that is responsible for symmetric dimethylation of arginine (SDMA) on histone and non-histone substrates
  • PRMT5 is highly overexpressed in many human cancers
  • Glioblastoma (GBM) with splicing dysregulation is selectively sensitive to inhibition of PRMT5
  • PRMT5 inhibition impairs the removal of detained introns leading to modulation of proliferation specific genes
  • GBM specific key tumor suppressor is silenced by PRMT5 leading to poor prognosis
  • Potential for patient stratification: targeting tumors with high CLNS1A/RIOK1 ratio


  • Brain-penetrant PRMT5 inhibitor to address the unmet medical need in treating GBM
  • Potential use in other cancers where PRMT5 is over expressed (lymphoma, pancreas, SCLC, etc) and in cancers with spliceosome dysregulation

We use cookies to recognize your repeat visits and preferences, as well as to measure the effectiveness
of campaigns and analyze traffic. If you continue to use this site we will assume your acceptance.